BERKELEY HEIGHTS, N.J. ( TheStreet) --Shares of Cyclacel Pharmaceuticals ( CYCC - Get Report) are higher Wednesday on a rumor that the prestigious New England Journal of Medicine (NEJM) was going to publish an article on the company's experimental cancer drug seliciclib in this week's issue arriving tonight.

Well, sorry to rain on traders' rally, but no such article exists. I know because I already have a copy of this week's NEJM and there is no article on Cyclacel or seliciclib.

The NEJM provides early, embargoed access to its weekly issues to members of the media. I'm not allowed to disclose the contents of the new NEJM until the embargo lifts tonight at 5 p.m. EST, but given the movement in the stock today, I do feel obligated to let anxious Cyclacel shareholders know not to expect an article on seliciclib.

Cyclacel shares were up 14% to $2.89 in recent trading.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.